Alignment Healthcare names tech expert as new COO

Technology expert Jennifer “Jenna” Geiger has been hired as Alignment Healthcare’s first chief operating officer (COO), according to a release from the population health management company.

With more than 25 years of technology and business experience, Geiger will be responsible for all technology, business, clinical operations, and overseeing the startup company’s continued growth.

"Alignment Healthcare has grown exponentially in the last two years, from 12 employees to more than 300, and we need a proven leader to ensure the daily ins and outs of the company are working smoothly as we continue to expand," said founder and CEO John Kao. "Jenna's expertise and experience working with operationally intensive businesses like ours, and her passion for health care made her a uniquely qualified candidate to take on this role."

Alignment Healthcare, founded in 2013, now serves about 30,000 Medicare beneficiaries in three states. The company aims to transform the process of medical treatment in the U.S. so that every link in the healthcare field becomes more efficient and effective. They have also implemented a patented technology-driven clinical model designed to provide concierge-level care to seniors at dramatically lower costs.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.